D-Serine: A Cross Species Review of Safety

Background: D- Serine, a direct, full agonist at the D- serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limite...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in psychiatry Vol. 12; p. 726365
Main Authors Meftah, Amir, Hasegawa, Hiroshi, Kantrowitz, Joshua T.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 10.08.2021
Subjects
D-serine
kidney
NMDA–N-methyl-D-aspartate
Psychiatry
safety
schizophrenia
Online AccessGet full text

Cover

Abstract Background: D- Serine, a direct, full agonist at the D- serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limited D- serine research in humans, particularly using high doses. A review of D- serine's safety is timely and pertinent, as D- serine remains under active study for schizophrenia, both directly (R61 MH116093) and indirectly through D- amino acid oxidase ( D AAO) inhibitors. The principal focus is on nephrotoxicity, but safety in other physiologic and pathophysiologic systems are also reviewed. Methods: Using the search terms “ D- serine,” “ D- serine and schizophrenia,” “ D- serine and safety,” “ D- serine and nephrotoxicity” in PubMed, we conducted a systematic review on D- serine safety. D- serine physiology, dose-response and efficacy in clinical studies and d AAO inhibitor safety is also discussed. Results: When D- serine doses >500 mg/kg are used in rats, nephrotoxicity, manifesting as an acute tubular necrosis syndrome, seen within hours of administration is highly common, if not universal. In other species, however, D -serine induced nephrotoxicity has not been reported, even in other rodent species such as mice and rabbits. Even in rats, D- -serine related toxicity is dose dependent and reversible; and does not appear to be present in rats at doses producing an acute Cmax of <2,000 nmol/mL. For comparison, the Cmax of D- serine 120 mg/kg, the highest dose tested in humans, is ~500 nmol/mL in acute dosing. Across all published human studies, only one subject has been reported to have abnormal renal values related to D- serine treatment. This abnormality did not clearly map on to the acute tubular necrosis syndrome seen in rats, and fully resolved within a few days of stopping treatment. D AAO inhibitors may be nephroprotective. D- Serine may have a physiologic role in metabolic, extra-pyramidal, cardiac and other systems, but no other clinically significant safety concerns are revealed in the literature. Conclusions: Even before considering human to rat differences in renal physiology, using current FDA guided monitoring paradigms, D- serine appears safe at currently studied maximal doses, with potential safety in combination with D AAO inhibitors.
AbstractList Background:D-Serine, a direct, full agonist at the D-serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limited D-serine research in humans, particularly using high doses. A review of D-serine's safety is timely and pertinent, as D-serine remains under active study for schizophrenia, both directly (R61 MH116093) and indirectly through D-amino acid oxidase (DAAO) inhibitors. The principal focus is on nephrotoxicity, but safety in other physiologic and pathophysiologic systems are also reviewed. Methods: Using the search terms "D-serine," "D-serine and schizophrenia," "D-serine and safety," "D-serine and nephrotoxicity" in PubMed, we conducted a systematic review on D-serine safety. D-serine physiology, dose-response and efficacy in clinical studies and dAAO inhibitor safety is also discussed. Results: When D-serine doses >500 mg/kg are used in rats, nephrotoxicity, manifesting as an acute tubular necrosis syndrome, seen within hours of administration is highly common, if not universal. In other species, however, D-serine induced nephrotoxicity has not been reported, even in other rodent species such as mice and rabbits. Even in rats, D--serine related toxicity is dose dependent and reversible; and does not appear to be present in rats at doses producing an acute Cmax of <2,000 nmol/mL. For comparison, the Cmax of D-serine 120 mg/kg, the highest dose tested in humans, is ~500 nmol/mL in acute dosing. Across all published human studies, only one subject has been reported to have abnormal renal values related to D-serine treatment. This abnormality did not clearly map on to the acute tubular necrosis syndrome seen in rats, and fully resolved within a few days of stopping treatment. DAAO inhibitors may be nephroprotective. D-Serine may have a physiologic role in metabolic, extra-pyramidal, cardiac and other systems, but no other clinically significant safety concerns are revealed in the literature. Conclusions: Even before considering human to rat differences in renal physiology, using current FDA guided monitoring paradigms, D-serine appears safe at currently studied maximal doses, with potential safety in combination with DAAO inhibitors.Background:D-Serine, a direct, full agonist at the D-serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limited D-serine research in humans, particularly using high doses. A review of D-serine's safety is timely and pertinent, as D-serine remains under active study for schizophrenia, both directly (R61 MH116093) and indirectly through D-amino acid oxidase (DAAO) inhibitors. The principal focus is on nephrotoxicity, but safety in other physiologic and pathophysiologic systems are also reviewed. Methods: Using the search terms "D-serine," "D-serine and schizophrenia," "D-serine and safety," "D-serine and nephrotoxicity" in PubMed, we conducted a systematic review on D-serine safety. D-serine physiology, dose-response and efficacy in clinical studies and dAAO inhibitor safety is also discussed. Results: When D-serine doses >500 mg/kg are used in rats, nephrotoxicity, manifesting as an acute tubular necrosis syndrome, seen within hours of administration is highly common, if not universal. In other species, however, D-serine induced nephrotoxicity has not been reported, even in other rodent species such as mice and rabbits. Even in rats, D--serine related toxicity is dose dependent and reversible; and does not appear to be present in rats at doses producing an acute Cmax of <2,000 nmol/mL. For comparison, the Cmax of D-serine 120 mg/kg, the highest dose tested in humans, is ~500 nmol/mL in acute dosing. Across all published human studies, only one subject has been reported to have abnormal renal values related to D-serine treatment. This abnormality did not clearly map on to the acute tubular necrosis syndrome seen in rats, and fully resolved within a few days of stopping treatment. DAAO inhibitors may be nephroprotective. D-Serine may have a physiologic role in metabolic, extra-pyramidal, cardiac and other systems, but no other clinically significant safety concerns are revealed in the literature. Conclusions: Even before considering human to rat differences in renal physiology, using current FDA guided monitoring paradigms, D-serine appears safe at currently studied maximal doses, with potential safety in combination with DAAO inhibitors.
Background: D- Serine, a direct, full agonist at the D- serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limited D- serine research in humans, particularly using high doses. A review of D- serine's safety is timely and pertinent, as D- serine remains under active study for schizophrenia, both directly (R61 MH116093) and indirectly through D- amino acid oxidase ( D AAO) inhibitors. The principal focus is on nephrotoxicity, but safety in other physiologic and pathophysiologic systems are also reviewed. Methods: Using the search terms “ D- serine,” “ D- serine and schizophrenia,” “ D- serine and safety,” “ D- serine and nephrotoxicity” in PubMed, we conducted a systematic review on D- serine safety. D- serine physiology, dose-response and efficacy in clinical studies and d AAO inhibitor safety is also discussed. Results: When D- serine doses >500 mg/kg are used in rats, nephrotoxicity, manifesting as an acute tubular necrosis syndrome, seen within hours of administration is highly common, if not universal. In other species, however, D -serine induced nephrotoxicity has not been reported, even in other rodent species such as mice and rabbits. Even in rats, D- -serine related toxicity is dose dependent and reversible; and does not appear to be present in rats at doses producing an acute Cmax of <2,000 nmol/mL. For comparison, the Cmax of D- serine 120 mg/kg, the highest dose tested in humans, is ~500 nmol/mL in acute dosing. Across all published human studies, only one subject has been reported to have abnormal renal values related to D- serine treatment. This abnormality did not clearly map on to the acute tubular necrosis syndrome seen in rats, and fully resolved within a few days of stopping treatment. D AAO inhibitors may be nephroprotective. D- Serine may have a physiologic role in metabolic, extra-pyramidal, cardiac and other systems, but no other clinically significant safety concerns are revealed in the literature. Conclusions: Even before considering human to rat differences in renal physiology, using current FDA guided monitoring paradigms, D- serine appears safe at currently studied maximal doses, with potential safety in combination with D AAO inhibitors.
Background:D-Serine, a direct, full agonist at the D-serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been assessed as a treatment for multiple psychiatric and neurological conditions. Based on studies in rats, concerns of nephrotoxicity have limited D-serine research in humans, particularly using high doses. A review of D-serine's safety is timely and pertinent, as D-serine remains under active study for schizophrenia, both directly (R61 MH116093) and indirectly through D-amino acid oxidase (DAAO) inhibitors. The principal focus is on nephrotoxicity, but safety in other physiologic and pathophysiologic systems are also reviewed.Methods: Using the search terms “D-serine,” “D-serine and schizophrenia,” “D-serine and safety,” “D-serine and nephrotoxicity” in PubMed, we conducted a systematic review on D-serine safety. D-serine physiology, dose-response and efficacy in clinical studies and dAAO inhibitor safety is also discussed.Results: When D-serine doses >500 mg/kg are used in rats, nephrotoxicity, manifesting as an acute tubular necrosis syndrome, seen within hours of administration is highly common, if not universal. In other species, however, D-serine induced nephrotoxicity has not been reported, even in other rodent species such as mice and rabbits. Even in rats, D--serine related toxicity is dose dependent and reversible; and does not appear to be present in rats at doses producing an acute Cmax of <2,000 nmol/mL. For comparison, the Cmax of D-serine 120 mg/kg, the highest dose tested in humans, is ~500 nmol/mL in acute dosing. Across all published human studies, only one subject has been reported to have abnormal renal values related to D-serine treatment. This abnormality did not clearly map on to the acute tubular necrosis syndrome seen in rats, and fully resolved within a few days of stopping treatment. DAAO inhibitors may be nephroprotective. D-Serine may have a physiologic role in metabolic, extra-pyramidal, cardiac and other systems, but no other clinically significant safety concerns are revealed in the literature.Conclusions: Even before considering human to rat differences in renal physiology, using current FDA guided monitoring paradigms, D-serine appears safe at currently studied maximal doses, with potential safety in combination with DAAO inhibitors.
Author Hasegawa, Hiroshi
Kantrowitz, Joshua T.
Meftah, Amir
AuthorAffiliation 2 New York State Psychiatric Institute , New York City, NY , United States
4 Nathan Kline Institute , Orangeburg, NY , United States
3 Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences , Tokyo , Japan
1 College of Physicians and Surgeons, Columbia University , New York City, NY , United States
AuthorAffiliation_xml – name: 2 New York State Psychiatric Institute , New York City, NY , United States
– name: 1 College of Physicians and Surgeons, Columbia University , New York City, NY , United States
– name: 4 Nathan Kline Institute , Orangeburg, NY , United States
– name: 3 Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences , Tokyo , Japan
Author_xml – sequence: 1
  givenname: Amir
  surname: Meftah
  fullname: Meftah, Amir
– sequence: 2
  givenname: Hiroshi
  surname: Hasegawa
  fullname: Hasegawa, Hiroshi
– sequence: 3
  givenname: Joshua T.
  surname: Kantrowitz
  fullname: Kantrowitz, Joshua T.
BookMark eNp1kV9LHDEUxUNR1Fo_QN_mUYTZ3vyZJNMHQbZWBUHots8hk9zYyOxkTWYt--2ddRVqofflXnLP-XHJ-Uj2hjQgIZ8pzDjX7ZewKptxxoDRmWKSy-YDOaJSihqkgL2_5kNyUsoDTMXbdtIdkEMuhFCciSNy9q1eYI4Dfq0uqnlOpVSLFbqIpfqBTxH_VClUCxtw3Hwi-8H2BU9e-zH59f3y5_y6vr27uplf3NauAT3W3oUmKNkAWNVS6sCxTrpgFXeMY6e8bhgGLbVvtBeWaw-UyjZ4DU5rB_yY3Oy4PtkHs8pxafPGJBvNy0PK98bmMboejfeK89BOwE4Iq_QE1JZCI1lHJYCYWOc71mrdLdE7HMZs-3fQ95sh_jb36clorgXlagKcvgJyelxjGc0yFod9bwdM62JYIyVw2XI-SdVO6rbfmDEYF0c7xrQlx95QMNvgzEtwZhuc2QU3Oek_zrcD_-95BhAZm2A
CitedBy_id crossref_primary_10_1016_j_biopsych_2023_01_015
crossref_primary_10_1093_ijnp_pyae066
crossref_primary_10_1093_ijnp_pyad011
crossref_primary_10_1016_j_biopsych_2024_08_019
crossref_primary_10_1038_s41380_023_02312_8
crossref_primary_10_3389_fcimb_2025_1518659
crossref_primary_10_3390_biomedicines10071462
crossref_primary_10_3390_ijms232415542
crossref_primary_10_1007_s40263_022_00959_5
crossref_primary_10_3389_fpsyt_2021_754032
crossref_primary_10_1007_s00203_024_03918_4
crossref_primary_10_3390_brainsci13081193
crossref_primary_10_1038_s41598_022_23769_7
crossref_primary_10_1093_nutrit_nuad008
crossref_primary_10_1002_syn_22252
crossref_primary_10_3390_biom14091128
crossref_primary_10_1016_j_schres_2024_06_017
crossref_primary_10_1016_j_molmed_2023_09_001
crossref_primary_10_3390_ijms231810613
crossref_primary_10_3390_ph15101297
Cites_doi 10.1007/BF01294720
10.1007/s11095-020-02893-x
10.1016/j.autneu.2018.09.004
10.1152/ajprenal.00461.2020
10.1016/j.tox.2004.08.008
10.1016/j.bcp.2010.02.007
10.1016/j.schres.2017.02.027
10.2174/138161211795049633
10.1016/j.molmet.2017.03.011
10.1016/j.pediatrneurol.2015.02.002
10.1093/brain/aww262
10.4088/JCP.11m07031
10.1016/0014-2999(92)94837-L
10.1073/pnas.1114639109
10.1017/S1461145711001386
10.3390/ijms17071081
10.1016/j.schres.2018.02.003
10.1097/FJC.0000000000000398
10.1177/1932296814553622
10.1016/j.ejphar.2012.09.011
10.1073/pnas.0914128107
10.3389/fncel.2013.00039
10.1016/j.tox.2006.10.008
10.1038/srep26137
10.1007/s13730-019-00411-6
10.1124/dmd.112.046482
10.1186/s13063-017-1908-5
10.1074/jbc.M112.380824
10.1016/j.brainres.2012.05.042
10.1080/19382014.2016.1260797
10.1097/00000542-199712000-00021
10.1160/TH03-02-0106
10.1016/S0140-6736(19)31135-3
10.3389/fpsyt.2021.653026
10.1097/JCP.0000000000000536
10.1007/s00125-015-3553-4
10.1101/cshperspect.a005710
10.1016/j.schres.2010.05.012
10.1016/j.neuropharm.2011.06.029
10.1038/sj.emboj.7601840
10.1023/A:1007064504007
10.1007/s00726-020-02892-7
10.1038/s41386-020-0706-z
10.1016/0014-5793(92)80397-Y
10.1097/JCP.0000000000000722
10.1038/nm.3822
10.1017/S1461145709990939
10.1176/ajp.156.11.1822
10.1371/journal.pone.0086504
10.1538/expanim1978.32.1_1
10.1038/s41537-019-0090-z
10.1176/appi.ajp.2007.07010042
10.1016/j.bpsc.2018.02.002
10.1021/tx030019q
10.1006/bbrc.1997.6724
10.1007/s10157-020-01862-3
10.1080/1354750X.2018.1528632
10.1152/ajprenal.90391.2008
10.1002/psc.3066
10.3390/nu11092205
10.1016/j.biopsych.2017.12.006
10.1016/j.molbrainres.2004.03.007
10.1080/00325481.2019.1701823
10.1016/S0021-9258(18)45040-5
10.1038/s41598-019-53302-2
10.1038/npp.2012.208
10.1001/jamapsychiatry.2019.4265
10.1021/acs.jafc.7b04217
10.4103/0976-0105.177703
10.1016/j.jpba.2018.09.026
10.1017/S1461145711001015
10.1016/S0006-3223(98)00279-0
10.1152/jn.1998.80.6.3336
10.1093/ndt/gfv028
10.1007/s00726-002-0317-5
10.1007/978-0-387-30410-6_3
10.1016/j.conb.2012.01.007
10.1001/archpsyc.62.11.1196
10.1371/journal.pone.0067131
10.1016/j.schres.2013.09.018
10.3390/cells10010093
10.1042/cs0730105
10.1177/0269881120908904
10.1038/s41598-017-11049-8
10.3109/15622975.2015.1117654
10.1111/j.1742-4658.2011.08354.x
10.1016/j.coph.2014.12.004
10.1152/ajprenal.1999.276.6.F857
10.1046/j.1471-4159.1997.69031286.x
10.1073/pnas.92.9.3948
10.1016/0305-0491(82)90490-4
10.1073/pnas.1304308110
10.1016/0006-8993(94)90240-2
10.1113/jphysiol.1984.sp015361
10.3390/ijms18071416
10.1073/pnas.96.2.721
10.1016/j.jpsychires.2014.12.007
10.1007/s002040000156
10.1152/ajprenal.00441.2006
10.1016/j.jchromb.2010.08.024
10.1016/0014-5793(95)00890-L
10.1080/21678421.2020.1832120
10.1016/j.neuint.2012.03.008
10.1007/s0054080020207
10.1124/jpet.112.194464
10.1021/jm800200u
10.1016/S2215-0366(16)30344-3
10.1111/j.1460-9568.2007.05769.x
10.1007/s002130050662
10.1093/schbul/13.2.261
10.1017/S1461145709000339
10.1176/appi.ajp.2016.16060735
10.1097/00000542-200301000-00021
10.1016/j.biopsych.2004.12.037
10.1111/j.1479-8425.2006.00193.x
10.1016/j.biopsych.2005.06.032
10.1152/ajpregu.00083.2015
10.1016/S2215-0366(20)30513-7
10.1016/j.schres.2014.07.052
10.3389/fpsyt.2018.00014
10.1016/S0378-4347(01)00131-1
10.20900/jpbs.20200018
10.1046/j.1471-4159.1995.65010454.x
10.1016/j.tox.2007.10.009
10.1038/tp.2015.52
10.1097/00000542-199301000-00022
10.1073/pnas.97.9.4926
10.1016/j.jpba.2018.10.047
10.1152/ajpcell.00268.2010
10.1007/s00424-017-2083-y
10.1016/j.neuropharm.2019.107681
10.1007/BF01695140
10.1016/j.brainresbull.2010.04.006
10.1038/s41598-019-41608-0
10.1016/j.biopsych.2009.01.002
10.1177/0269881120965937
10.1016/j.schres.2018.04.011
10.1248/bpb.21.156
10.1038/npp.2014.326
10.1016/j.biopsych.2014.08.023
10.1016/j.ejphar.2013.04.046
10.18632/oncotarget.7691
10.1016/j.molmet.2018.07.002
10.1016/0014-4800(79)90054-6
10.1016/j.neulet.2016.10.006
10.1016/S2215-0366(15)00098-X
10.3389/fpsyt.2021.514579
10.1074/jbc.M405726200
10.1016/j.schres.2016.10.027
10.1213/00000539-197409000-00015
10.1177/1533317514545379
10.1016/j.neuint.2011.08.017
10.1021/tx0500326
10.1007/s00535-021-01792-1.
10.1001/jamapsychiatry.2013.2159
10.1016/j.neulet.2018.05.039
10.1177/34.12.2878022
ContentType Journal Article
Copyright Copyright © 2021 Meftah, Hasegawa and Kantrowitz.
Copyright © 2021 Meftah, Hasegawa and Kantrowitz. 2021 Meftah, Hasegawa and Kantrowitz
Copyright_xml – notice: Copyright © 2021 Meftah, Hasegawa and Kantrowitz.
– notice: Copyright © 2021 Meftah, Hasegawa and Kantrowitz. 2021 Meftah, Hasegawa and Kantrowitz
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fpsyt.2021.726365
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
EISSN 1664-0640
ExternalDocumentID oai_doaj_org_article_dd733f952eb44a788d48a10562b16004
PMC8384137
10_3389_fpsyt_2021_726365
GrantInformation_xml – fundername: National Institute of Mental Health
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ABIVO
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c508t-dcf5f76500a7911c0c2b6cfa73c23eb7d852ef868d58d4a38d01169fd80c88c03
IEDL.DBID M48
ISSN 1664-0640
IngestDate Wed Aug 27 01:30:27 EDT 2025
Thu Aug 21 18:21:13 EDT 2025
Fri Jul 11 13:02:49 EDT 2025
Thu Apr 24 23:04:04 EDT 2025
Tue Jul 01 03:12:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-dcf5f76500a7911c0c2b6cfa73c23eb7d852ef868d58d4a38d01169fd80c88c03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Natasa Petronijevic, University of Belgrade, Serbia
Reviewed by: Jumpei Sasabe, Keio University, Japan; Kenji Hashimoto, Chiba University, Japan
This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fpsyt.2021.726365
PMID 34447324
PQID 2566036933
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_dd733f952eb44a788d48a10562b16004
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8384137
proquest_miscellaneous_2566036933
crossref_citationtrail_10_3389_fpsyt_2021_726365
crossref_primary_10_3389_fpsyt_2021_726365
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-08-10
PublicationDateYYYYMMDD 2021-08-10
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-10
  day: 10
PublicationDecade 2020
PublicationTitle Frontiers in psychiatry
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Tsai (B52) 1998; 44
Hons (B75) 2021; 12
Carone (B86) 1975; 99
Anderson (B80) 2011; 300
Yoneyama (B159) 2020; 37
Kawai (B126) 2015; 40
Lane (B155) 2013; 70
Deng (B79) 2009; 296
Hasegawa (B108) 2019; 162
Foltyn (B20) 2005; 280
Heresco-Levy (B51) 2015; 77
Verrall (B26) 2007; 26
Horiike (B21) 1994; 652
Morikawa (B23) 2001; 757
Hashimoto (B163) 2009; 65
Hesaka (B107) 2019; 8
Gillies (B145) 2018; 216
Kaltenbach (B89) 1979; 30
Lee (B135) 2021; 22
Fleischhacker (B5) 2021; 8
Bugarski-Kirola (B6) 2016; 3
Brummel (B78) 2018
Javitt (B71) 2008
Watanabe (B40) 1992; 223
Grabb (B9) 2016; 36
Ghasemi (B127) 2010; 79
Moreno (B22) 1999; 28
Gonzalez-Hernandez (B137) 2003; 24
Kantrowitz (B76) 2018; 3
Pallerla (B154) 2018; 24
Marquard (B115) 2015; 21
Aya (B142) 1997; 87
Nuechterlein (B73) 2008; 165
Krug (B91) 2007; 293
Nilsson (B72) 1997; 104
Morehead (B83) 1945; 21
Lockridge (B117) 2016; 8
Andreasen (B68) 1984
Ivanov (B44) 2019; 689
Van Horn (B43) 2013; 7
Lin (B157) 2017; 18
Otte (B38) 2013; 8
Ganote (B85) 1974; 77
Huang (B90) 1998; 21
Jin (B149) 2003; 98
Dunlop (B18) 1997; 235
Sasabe (B30) 2012; 109
Usuda (B94) 1986; 34
Hunt (B41) 2012; 22
Inagawa (B125) 2006; 4
Malkesman (B66) 2012; 15
Du (B151) 2019; 164
Guercio (B39) 2018; 9
Lemmon (B61) 2015; 52
Nair (B165) 2016; 7
Horio (B28) 2011; 59
Kantrowitz (B48) 2018; 191
Kay (B69) 1987; 13
Ndiaye (B118) 2017; 6
Mothet (B37) 2000; 97
Kantrowitz (B77) 2019; 207
Asakawa (B138) 2021
Morehead (B84) 1946; 21
Shimizu (B129) 2017; 18
Cobb (B124) 2015; 9
Hashimoto (B13) 1992; 296
Bastings (B150) 2019; 11
Sasabe (B134) 2007; 26
Williams (B160) 2005; 207
Takahashi (B32) 1997; 69
Cho (B46) 2016; 634
Maekawa (B29) 2005; 18
Kantrowitz (B47) 2015; 2
D'souza (B59) 2013; 38
Levin (B62) 2015; 61
Silbernagl (B88) 1999; 276
Iwakawa (B101) 2019; 24
Mitchell (B133) 2010; 107
Hoka (B147) 1988; 2
Ermilov (B49) 2013; 150
Priestley (B35) 1995; 48
Molnar (B114) 1995; 371
Suzuki (B112) 2012; 1466
Strick (B25) 2011; 61
Weiser (B60) 2012; 73
Capitao (B50) 2020; 34
Heresco-Levy (B56) 2009; 12
Heresco-Levy (B54) 2005; 57
Madeira (B65) 2015; 5
Balu (B16) 2015; 20
Tsai (B70) 2006; 59
Camargo (B143) 2013; 713
Slogoff (B146) 1974; 53
Ferraris (B162) 2008; 51
Lane (B57) 2010; 13
Gonzalez-Hernandez (B153) 2014; 159
Ferreira-Junior (B144) 2018; 470
Ferraris (B164) 2011; 17
Kantrowitz (B4) 2016; 139
Avellar (B63) 2016; 7
Ogawa (B148) 1993; 78
Dunayevich (B7) 2017; 182
Matsui (B34) 1995; 65
Ghasemi-Kasman (B139) 2012; 696
Lane (B55) 2005; 62
Van Berckel (B130) 1998; 138
Kantrowitz (B31) 2010; 121
Fishman (B82) 1942; 145
Sasaki (B122) 2016; 17
Potkin (B2) 2020; 6
Dryer (B81) 2015; 30
Nagata (B104) 1987; 73
Mcgee (B141) 2012; 342
Schell (B14) 1995; 92
Tseng (B98) 2021; 320
Huhn (B110) 2019; 394
Konno (B161) 2000; 74
Okada (B109) 2017; 7
Hesaka (B106) 2019; 9
Sasaki (B121) 2015; 309
Kantrowitz (B11) 2009
Suzuki (B102) 2019; 9
Suwandhi (B119) 2018; 16
Gelfin (B58) 2012; 15
Wei (B67) 2017; 65
Bentley-Lewis (B123) 2015; 58
Kantrowitz (B1) 2020; 45
Kantrowitz (B12) 2010; 83
Balu (B15) 2013; 110
Chieffi Baccari (B17) 2020; 52
Meftah (B111) 2020; 132
Konno (B96) 1982; 71
Perotti (B95) 1987; 19
Yamauchi (B120) 1983; 32
Mcgee (B140) 2016; 68
Wegner (B64) 2019; 157
Yang (B113) 2015; 30
Williams (B87) 2003; 16
Lockridge (B116) 2021; 10
Wolosker (B19) 1999; 96
Panizzutti (B74) 2019; 207
Kimura (B100) 2020; 24
Dong (B132) 2021; 12
Berger (B36) 1998; 80
De La Garrigue (B10) 2020; 5
Rais (B136) 2012; 40
Kantrowitz (B8) 2017; 37
Kimura (B105) 2016; 6
Pernot (B33) 2012; 60
Frattini (B97) 2011; 278
Kantrowitz (B131) 2016; 173
Lin (B156) 2017; 84
Goh (B3) 2021; 35
Tsai (B53) 1999; 156
Xia (B27) 2004; 125
Luscher (B42) 2012; 4
Orozco-Ibarra (B92) 2007; 229
Kantrowitz (B128) 2020; 77
Sasabe (B103) 2014; 9
Soto (B93) 2008; 243
Kragh-Hansen (B99) 1984; 354
Diniz (B45) 2012; 287
Ryan (B158) 2017; 18
Piossek (B152) 2003; 90
Miyoshi (B24) 2011; 879
References_xml – volume: 104
  start-page: 1195
  year: 1997
  ident: B72
  article-title: Glycine and D-serine decrease MK-801-induced hyperactivity in mice
  publication-title: J Neural Transm.
  doi: 10.1007/BF01294720
– volume: 37
  start-page: 164
  year: 2020
  ident: B159
  article-title: Mechanistic multilayer quantitative model for nonlinear pharmacokinetics, target occupancy and pharmacodynamics (PK/TO/PD) Relationship of d-amino acid oxidase inhibitor, TAK-831 in mice
  publication-title: Pharm Res.
  doi: 10.1007/s11095-020-02893-x
– volume: 216
  start-page: 51
  year: 2018
  ident: B145
  article-title: Direct neurophysiological evidence for a role of the human anterior cingulate cortex in central command
  publication-title: Auton Neurosci
  doi: 10.1016/j.autneu.2018.09.004
– volume: 320
  start-page: F799
  year: 2021
  ident: B98
  article-title: N-methyl-d-aspartate receptor hyperfunction contributes to D-serine-mediated renal insufficiency
  publication-title: Am J Physiol Renal Physiol.
  doi: 10.1152/ajprenal.00461.2020
– volume: 207
  start-page: 35
  year: 2005
  ident: B160
  article-title: Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat
  publication-title: Toxicology.
  doi: 10.1016/j.tox.2004.08.008
– volume: 99
  start-page: 658
  year: 1975
  ident: B86
  article-title: D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis
  publication-title: Arch Pathol.
– volume: 79
  start-page: 1791
  year: 2010
  ident: B127
  article-title: d-Serine modulates neurogenic relaxation in rat corpus cavernosum
  publication-title: Biochem Pharmacol.
  doi: 10.1016/j.bcp.2010.02.007
– volume: 191
  start-page: 70
  year: 2018
  ident: B48
  article-title: Improvement in mismatch negativity generation during D-serine treatment in schizophrenia: correlation with symptoms
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2017.02.027
– volume: 17
  start-page: 103
  year: 2011
  ident: B164
  article-title: Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia
  publication-title: Curr Pharm Des.
  doi: 10.2174/138161211795049633
– volume: 6
  start-page: 459
  year: 2017
  ident: B118
  article-title: Expression and functional assessment of candidate type 2 diabetes susceptibility genes identify four new genes contributing to human insulin secretion
  publication-title: Mol Metab.
  doi: 10.1016/j.molmet.2017.03.011
– volume: 52
  start-page: 629
  year: 2015
  ident: B61
  article-title: Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of D-serine and riluzole in tourette syndrome
  publication-title: Pediatr Neurol.
  doi: 10.1016/j.pediatrneurol.2015.02.002
– volume: 139
  start-page: 3281
  year: 2016
  ident: B4
  article-title: Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
  publication-title: Brain.
  doi: 10.1093/brain/aww262
– volume: 73
  start-page: e728
  year: 2012
  ident: B60
  article-title: A multicenter, add-on randomized controlled trial of low-dose D-serine for negative and cognitive symptoms of schizophrenia
  publication-title: J Clin Psychiatry.
  doi: 10.4088/JCP.11m07031
– volume: 223
  start-page: 179
  year: 1992
  ident: B40
  article-title: Effects of glycine and structurally related amino acids on generation of long-term potentiation in rat hippocampal slices
  publication-title: Eur J Pharmacol.
  doi: 10.1016/0014-2999(92)94837-L
– volume: 109
  start-page: 627
  year: 2012
  ident: B30
  article-title: D-amino acid oxidase controls motoneuron degeneration through D-serine
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.1114639109
– volume: 15
  start-page: 1135
  year: 2012
  ident: B66
  article-title: Acute D-serine treatment produces antidepressant-like effects in rodents
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145711001386
– volume: 17
  start-page: 1081
  year: 2016
  ident: B122
  article-title: Control of appetite and food preference by nmda receptor and its co-agonist D-serine
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms17071081
– volume: 207
  start-page: 70
  year: 2019
  ident: B77
  article-title: N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2018.02.003
– volume: 68
  start-page: 97
  year: 2016
  ident: B140
  article-title: N-Methyl-D-Aspartate receptor signaling and function in cardiovascular tissues
  publication-title: J Cardiovasc Pharmacol.
  doi: 10.1097/FJC.0000000000000398
– volume: 9
  start-page: 69
  year: 2015
  ident: B124
  article-title: A novel test for IGT utilizing metabolite markers of glucose tolerance
  publication-title: J Diabetes Sci Technol.
  doi: 10.1177/1932296814553622
– volume: 696
  start-page: 155
  year: 2012
  ident: B139
  article-title: D-serine modulates non-adrenergic non-cholinergic contraction of lower esophageal sphincter in rats
  publication-title: Eur J Pharmacol.
  doi: 10.1016/j.ejphar.2012.09.011
– volume: 107
  start-page: 7556
  year: 2010
  ident: B133
  article-title: Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0914128107
– volume: 7
  start-page: 39
  year: 2013
  ident: B43
  article-title: D-serine as a gliotransmitter and its roles in brain development and disease
  publication-title: Front Cell Neurosci.
  doi: 10.3389/fncel.2013.00039
– volume: 229
  start-page: 123
  year: 2007
  ident: B92
  article-title: Evaluation of oxidative stress in D-serine induced nephrotoxicity
  publication-title: Toxicology.
  doi: 10.1016/j.tox.2006.10.008
– start-page: 33
  year: 2008
  ident: B71
  article-title: Dose-finding PK/PD study of D-serine in schizophrenia: effects on symptoms and neurocognition
  publication-title: Neuropharmacology
– volume: 6
  start-page: 26137
  year: 2016
  ident: B105
  article-title: Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease
  publication-title: Sci Rep.
  doi: 10.1038/srep26137
– volume: 8
  start-page: 297
  year: 2019
  ident: B107
  article-title: Dynamics of D-serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis
  publication-title: CEN Case Rep.
  doi: 10.1007/s13730-019-00411-6
– volume: 40
  start-page: 2067
  year: 2012
  ident: B136
  article-title: Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice
  publication-title: Drug Metab Dispos.
  doi: 10.1124/dmd.112.046482
– volume: 18
  start-page: 165
  year: 2017
  ident: B158
  article-title: The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial
  publication-title: Trials.
  doi: 10.1186/s13063-017-1908-5
– volume: 287
  start-page: 41432
  year: 2012
  ident: B45
  article-title: Astrocyte-induced synaptogenesis is mediated by transforming growth factor beta signaling through modulation of D-serine levels in cerebral cortex neurons
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M112.380824
– volume: 1466
  start-page: 167
  year: 2012
  ident: B112
  article-title: Type 1 diabetes mellitus in mice increases hippocampal D-serine in the acute phase after streptozotocin injection
  publication-title: Brain Res.
  doi: 10.1016/j.brainres.2012.05.042
– volume: 8
  start-page: 195
  year: 2016
  ident: B117
  article-title: Serine racemase is expressed in islets and contributes to the regulation of glucose homeostasis
  publication-title: Islets.
  doi: 10.1080/19382014.2016.1260797
– volume: 87
  start-page: 1417
  year: 1997
  ident: B142
  article-title: Effects of ketamine on ventricular conduction, refractoriness, and wavelength: potential antiarrhythmic effects: a high-resolution epicardial mapping in rabbit hearts
  publication-title: Anesthesiology.
  doi: 10.1097/00000542-199712000-00021
– volume: 90
  start-page: 501
  year: 2003
  ident: B152
  article-title: Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2
  publication-title: Thromb Haemost.
  doi: 10.1160/TH03-02-0106
– volume: 394
  start-page: 939
  year: 2019
  ident: B110
  article-title: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(19)31135-3
– volume: 12
  start-page: 863
  year: 2021
  ident: B132
  article-title: Relationship of brain glutamate response to D-cycloserine and lurasidone to antidepressant response in bipolar depression: a pilot study
  publication-title: Front Psychiatry.
  doi: 10.3389/fpsyt.2021.653026
– volume: 36
  start-page: 419
  year: 2016
  ident: B9
  article-title: Derisking psychiatric drug development: the NIMH's fast fail program, a novel precompetitive model
  publication-title: J Clin Psychopharmacol.
  doi: 10.1097/JCP.0000000000000536
– volume: 58
  start-page: 1329
  year: 2015
  ident: B123
  article-title: Metabolomic profiling in the prediction of gestational diabetes mellitus
  publication-title: Diabetologia.
  doi: 10.1007/s00125-015-3553-4
– volume: 4
  start-page: a005710
  year: 2012
  ident: B42
  article-title: NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD)
  publication-title: Cold Spring Harb Perspect Biol
  doi: 10.1101/cshperspect.a005710
– volume: 121
  start-page: 125
  year: 2010
  ident: B31
  article-title: High dose D-serine in the treatment of schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2010.05.012
– volume: 61
  start-page: 1001
  year: 2011
  ident: B25
  article-title: Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain
  publication-title: Neuropharmacology.
  doi: 10.1016/j.neuropharm.2011.06.029
– volume: 26
  start-page: 4149
  year: 2007
  ident: B134
  article-title: D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis
  publication-title: EMBO J.
  doi: 10.1038/sj.emboj.7601840
– volume: 28
  start-page: 169
  year: 1999
  ident: B22
  article-title: Immunocytochemical localization of D-amino acid oxidase in rat brain
  publication-title: J Neurocytol.
  doi: 10.1023/A:1007064504007
– volume: 52
  start-page: 1263
  year: 2020
  ident: B17
  article-title: D-Amino acids in mammalian endocrine tissues
  publication-title: Amino Acids.
  doi: 10.1007/s00726-020-02892-7
– volume: 45
  start-page: 1842
  year: 2020
  ident: B1
  article-title: Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/s41386-020-0706-z
– volume: 296
  start-page: 33
  year: 1992
  ident: B13
  article-title: The presence of free D-serine in rat brain
  publication-title: FEBS Lett.
  doi: 10.1016/0014-5793(92)80397-Y
– volume: 37
  start-page: 447
  year: 2017
  ident: B8
  article-title: Neurophysiological effects of bitopertin in schizophrenia
  publication-title: J Clin Psychopharmacol.
  doi: 10.1097/JCP.0000000000000722
– volume: 21
  start-page: 363
  year: 2015
  ident: B115
  article-title: Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment
  publication-title: Nat Med.
  doi: 10.1038/nm.3822
– volume: 13
  start-page: 451
  year: 2010
  ident: B57
  article-title: A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145709990939
– volume: 156
  start-page: 1822
  year: 1999
  ident: B53
  article-title: D-serine added to clozapine for the treatment of schizophrenia
  publication-title: Am J Psychiatry.
  doi: 10.1176/ajp.156.11.1822
– volume: 9
  start-page: e86504
  year: 2014
  ident: B103
  article-title: Ischemic acute kidney injury perturbs homeostasis of serine enantiomers in the body fluid in mice: early detection of renal dysfunction using the ratio of serine enantiomers
  publication-title: PLoS ONE.
  doi: 10.1371/journal.pone.0086504
– volume: 32
  start-page: 1
  year: 1983
  ident: B120
  article-title: Effects of room temperature on reproduction, body and organ weights, food and water intakes, and hematology in mice
  publication-title: Jikken Dobutsu.
  doi: 10.1538/expanim1978.32.1_1
– volume: 6
  start-page: 1
  year: 2020
  ident: B2
  article-title: The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
  publication-title: NPJ Schizophr.
  doi: 10.1038/s41537-019-0090-z
– volume: 165
  start-page: 203
  year: 2008
  ident: B73
  article-title: The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity
  publication-title: Am J Psychiatry.
  doi: 10.1176/appi.ajp.2007.07010042
– volume: 3
  start-page: 581
  year: 2018
  ident: B76
  article-title: Auditory system target engagement during plasticity-based interventions in schizophrenia: a focus on modulation of n-methyl-d-aspartate-type glutamate receptor function
  publication-title: Biol Psychiatry Cogn Neurosci Neuroimaging.
  doi: 10.1016/j.bpsc.2018.02.002
– volume: 16
  start-page: 1207
  year: 2003
  ident: B87
  article-title: 1H NMR pattern recognition and 31P NMR studies with d-Serine in rat urine and kidney, time- and dose-related metabolic effects
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx030019q
– volume: 235
  start-page: 26
  year: 1997
  ident: B18
  article-title: The origin and turnover of D-serine in brain
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1006/bbrc.1997.6724
– volume: 24
  start-page: 404
  year: 2020
  ident: B100
  article-title: D-Amino acids and kidney diseases
  publication-title: Clin Exp Nephrol.
  doi: 10.1007/s10157-020-01862-3
– volume: 24
  start-page: 159
  year: 2019
  ident: B101
  article-title: Urinary D-serine level as a predictive biomarker for deterioration of renal function in patients with atherosclerotic risk factors
  publication-title: Biomarkers.
  doi: 10.1080/1354750X.2018.1528632
– volume: 296
  start-page: F976
  year: 2009
  ident: B79
  article-title: Renal NMDA receptors independently stimulate proximal reabsorption and glomerular filtration
  publication-title: Am J Physiol Renal Physiol.
  doi: 10.1152/ajprenal.90391.2008
– volume: 24
  start-page: e3066
  year: 2018
  ident: B154
  article-title: Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3
  publication-title: J Pept Sci.
  doi: 10.1002/psc.3066
– volume: 11
  start-page: 2205
  year: 2019
  ident: B150
  article-title: D-amino acids in health and disease: a focus on cancer
  publication-title: Nutrients
  doi: 10.3390/nu11092205
– volume: 84
  start-page: 422
  year: 2017
  ident: B156
  article-title: Sodium benzoate, a d-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2017.12.006
– volume: 125
  start-page: 96
  year: 2004
  ident: B27
  article-title: Characterization and localization of a human serine racemase
  publication-title: Brain Res Mol Brain Res.
  doi: 10.1016/j.molbrainres.2004.03.007
– volume: 48
  start-page: 841
  year: 1995
  ident: B35
  article-title: Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells
  publication-title: Mol Pharmacol.
– volume: 132
  start-page: 80
  year: 2020
  ident: B111
  article-title: New discoveries for an old drug: a review of recent olanzapine research
  publication-title: Postgrad Med.
  doi: 10.1080/00325481.2019.1701823
– volume: 145
  start-page: 345
  year: 1942
  ident: B82
  article-title: Serine injury
  publication-title: J Biol Chem.
  doi: 10.1016/S0021-9258(18)45040-5
– volume: 9
  start-page: 16705
  year: 2019
  ident: B102
  article-title: Serum D-serine accumulation after proximal renal tubular damage involves neutral amino acid transporter Asc-1
  publication-title: Sci Rep.
  doi: 10.1038/s41598-019-53302-2
– volume: 38
  start-page: 492
  year: 2013
  ident: B59
  article-title: Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2012.208
– volume: 77
  start-page: 343
  year: 2020
  ident: B128
  article-title: The potential role of lumateperone-something borrowed? Something new?
  publication-title: JAMA Psychiatry.
  doi: 10.1001/jamapsychiatry.2019.4265
– volume: 65
  start-page: 10792
  year: 2017
  ident: B67
  article-title: Acute amino acid D-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms
  publication-title: J Agric Food Chem.
  doi: 10.1021/acs.jafc.7b04217
– volume: 7
  start-page: 27
  year: 2016
  ident: B165
  article-title: A simple practice guide for dose conversion between animals and human
  publication-title: J Basic Clin Pharm.
  doi: 10.4103/0976-0105.177703
– volume: 162
  start-page: 264
  year: 2019
  ident: B108
  article-title: Pharmacokinetics and toxicokinetics of D-serine in rats
  publication-title: J Pharm Biomed Anal.
  doi: 10.1016/j.jpba.2018.09.026
– volume: 15
  start-page: 543
  year: 2012
  ident: B58
  article-title: D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145711001015
– volume: 44
  start-page: 1081
  year: 1998
  ident: B52
  article-title: D-serine added to antipsychotics for the treatment of schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/S0006-3223(98)00279-0
– volume: 80
  start-page: 3336
  year: 1998
  ident: B36
  article-title: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses
  publication-title: J Neurophysiol.
  doi: 10.1152/jn.1998.80.6.3336
– volume: 30
  start-page: 1630
  year: 2015
  ident: B81
  article-title: Glutamate receptors in the kidney
  publication-title: Nephrol Dial Transplant.
  doi: 10.1093/ndt/gfv028
– volume: 24
  start-page: 163
  year: 2003
  ident: B137
  article-title: Effect of D-amino acids on some mitochondrial functions in rat liver
  publication-title: Amino Acids.
  doi: 10.1007/s00726-002-0317-5
– volume-title: Handbook of Neurochemistry and Molecular Neurobiology
  year: 2009
  ident: B11
  article-title: Glutamatergic approaches to the conceptualization and treatment of schizophrenia
  doi: 10.1007/978-0-387-30410-6_3
– volume: 22
  start-page: 496
  year: 2012
  ident: B41
  article-title: Synaptic plasticity of NMDA receptors: mechanisms and functional implications
  publication-title: Curr Opin Neurobiol.
  doi: 10.1016/j.conb.2012.01.007
– volume: 62
  start-page: 1196
  year: 2005
  ident: B55
  article-title: Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
  publication-title: Arch Gen Psychiatry.
  doi: 10.1001/archpsyc.62.11.1196
– volume: 8
  start-page: e67131
  year: 2013
  ident: B38
  article-title: Effects of chronic D-serine elevation on animal models of depression and anxiety-related behavior
  publication-title: PLoS ONE.
  doi: 10.1371/journal.pone.0067131
– volume: 150
  start-page: 604
  year: 2013
  ident: B49
  article-title: A pilot double-blind comparison of D-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2013.09.018
– volume: 10
  start-page: 93
  year: 2021
  ident: B116
  article-title: Acute D-serine Co-Agonism of beta-Cell NMDA receptors potentiates glucose-stimulated insulin secretion and excitatory beta-cell membrane activity
  publication-title: Cells
  doi: 10.3390/cells10010093
– volume: 73
  start-page: 105
  year: 1987
  ident: B104
  article-title: Free D-amino acids in human plasma in relation to senescence and renal diseases
  publication-title: Clin Sci.
  doi: 10.1042/cs0730105
– volume: 34
  start-page: 557
  year: 2020
  ident: B50
  article-title: A single administration of 'microbial' D-alanine to healthy volunteers augments reaction to negative emotions: a comparison with D-serine
  publication-title: J Psychopharmacol.
  doi: 10.1177/0269881120908904
– volume: 7
  start-page: 11168
  year: 2017
  ident: B109
  article-title: D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation
  publication-title: Sci Rep.
  doi: 10.1038/s41598-017-11049-8
– volume: 18
  start-page: 357
  year: 2017
  ident: B157
  article-title: Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial
  publication-title: World J Biol Psychiatry.
  doi: 10.3109/15622975.2015.1117654
– volume: 278
  start-page: 4362
  year: 2011
  ident: B97
  article-title: Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase
  publication-title: FEBS J.
  doi: 10.1111/j.1742-4658.2011.08354.x
– volume: 20
  start-page: 109
  year: 2015
  ident: B16
  article-title: The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond
  publication-title: Curr Opin Pharmacol.
  doi: 10.1016/j.coph.2014.12.004
– volume: 276
  start-page: F857
  year: 1999
  ident: B88
  article-title: D-Serine is reabsorbed in rat renal pars recta
  publication-title: Am J Physiol.
  doi: 10.1152/ajprenal.1999.276.6.F857
– volume: 69
  start-page: 1286
  year: 1997
  ident: B32
  article-title: In vivo evidence for the link between L- and D-serine metabolism in rat cerebral cortex
  publication-title: J Neurochem.
  doi: 10.1046/j.1471-4159.1997.69031286.x
– volume: 92
  start-page: 3948
  year: 1995
  ident: B14
  article-title: D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.92.9.3948
– volume: 71
  start-page: 735
  year: 1982
  ident: B96
  article-title: Intraspecies and interspecies variations in the substrate specificity of D-amino acid oxidase
  publication-title: Comp Biochem Physiol B.
  doi: 10.1016/0305-0491(82)90490-4
– volume: 110
  start-page: E2400
  year: 2013
  ident: B15
  article-title: Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.1304308110
– volume: 652
  start-page: 297
  year: 1994
  ident: B21
  article-title: D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(94)90240-2
– volume: 354
  start-page: 55
  year: 1984
  ident: B99
  article-title: Serine uptake by luminal and basolateral membrane vesicles from rabbit kidney
  publication-title: J Physiol.
  doi: 10.1113/jphysiol.1984.sp015361
– volume: 18
  start-page: 1416
  year: 2017
  ident: B129
  article-title: Glycine-Binding site stimulants of NMDA receptors alleviate extrapyramidal motor disorders by activating the nigrostriatal dopaminergic pathway
  publication-title: Int J Mol Sic
  doi: 10.3390/ijms18071416
– volume: 96
  start-page: 721
  year: 1999
  ident: B19
  article-title: Purification of serine racemase: biosynthesis of the neuromodulator D- serine
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.96.2.721
– volume: 61
  start-page: 188
  year: 2015
  ident: B62
  article-title: Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
  publication-title: J Psychiatr Res.
  doi: 10.1016/j.jpsychires.2014.12.007
– volume-title: : ACT 39th Annual Meeting
  year: 2018
  ident: B78
  article-title: CTP-692: selective deuterium modification of D-serine markedly decreases renal toxicity in preclinical testing
– volume: 74
  start-page: 473
  year: 2000
  ident: B161
  article-title: Nephrotoxicity of D-proparglyglycine in mice
  publication-title: Arch Toxicol.
  doi: 10.1007/s002040000156
– volume: 293
  start-page: F382
  year: 2007
  ident: B91
  article-title: Why is D-serine nephrotoxic and alpha-aminoisobutyric acid protective?
  publication-title: Am J Physiol Renal Physiol.
  doi: 10.1152/ajprenal.00441.2006
– volume: 879
  start-page: 3184
  year: 2011
  ident: B24
  article-title: Simultaneous two-dimensional HPLC determination of free D-serine and D-alanine in the brain and periphery of mutant rats lacking D-amino-acid oxidase
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci.
  doi: 10.1016/j.jchromb.2010.08.024
– volume: 371
  start-page: 253
  year: 1995
  ident: B114
  article-title: Identification of functional ionotropic glutamate receptor proteins in pancreatic beta-cells and in islets of langerhans
  publication-title: FEBS Lett.
  doi: 10.1016/0014-5793(95)00890-L
– volume: 22
  start-page: 206
  year: 2021
  ident: B135
  article-title: Elevated plasma levels of D-serine in some patients with amyotrophic lateral sclerosis
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener.
  doi: 10.1080/21678421.2020.1832120
– volume: 60
  start-page: 837
  year: 2012
  ident: B33
  article-title: d-Serine diffusion through the blood-brain barrier: effect on D-serine compartmentalization and storage
  publication-title: Neurochem Int.
  doi: 10.1016/j.neuint.2012.03.008
– volume: 2
  start-page: 207
  year: 1988
  ident: B147
  article-title: Preservation of baroreflex control of vascular resistance under ketamine anesthesia in rats
  publication-title: J Anesth.
  doi: 10.1007/s0054080020207
– volume: 342
  start-page: 461
  year: 2012
  ident: B141
  article-title: Enhanced vascular neuronal nitric-oxide synthase-derived nitric-oxide production underlies the pressor response caused by peripheral N-methyl-D-aspartate receptor activation in conscious rats
  publication-title: J Pharmacol Exp Ther.
  doi: 10.1124/jpet.112.194464
– volume: 51
  start-page: 3357
  year: 2008
  ident: B162
  article-title: Synthesis and biological evaluation of D-amino acid oxidase inhibitors
  publication-title: J Med Chem.
  doi: 10.1021/jm800200u
– volume: 3
  start-page: 1115
  year: 2016
  ident: B6
  article-title: Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(16)30344-3
– volume: 26
  start-page: 1657
  year: 2007
  ident: B26
  article-title: d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia
  publication-title: Eur J Neurosci.
  doi: 10.1111/j.1460-9568.2007.05769.x
– volume: 138
  start-page: 190
  year: 1998
  ident: B130
  article-title: The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers
  publication-title: Psychopharmacology.
  doi: 10.1007/s002130050662
– volume: 13
  start-page: 261
  year: 1987
  ident: B69
  article-title: The positive and negative syndrome scale (PANSS) for schizophrenia
  publication-title: Schizophr Bull.
  doi: 10.1093/schbul/13.2.261
– volume: 12
  start-page: 1275
  year: 2009
  ident: B56
  article-title: Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145709000339
– volume: 173
  start-page: 1241
  year: 2016
  ident: B131
  article-title: d-Cycloserine, an NMDA glutamate receptor glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and GABA comparable to ketamine
  publication-title: Am J Psychiatry.
  doi: 10.1176/appi.ajp.2016.16060735
– volume: 98
  start-page: 121
  year: 2003
  ident: B149
  article-title: Ketamine differentially blocks sensory afferent synaptic transmission in medial nucleus tractus solitarius (mNTS)
  publication-title: Anesthesiology.
  doi: 10.1097/00000542-200301000-00021
– volume: 57
  start-page: 577
  year: 2005
  ident: B54
  article-title: D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2004.12.037
– volume: 4
  start-page: 75
  year: 2006
  ident: B125
  article-title: Subjective effects of glycine ingestion before bedtime on sleep quality
  publication-title: Sleep Biol Rhythms.
  doi: 10.1111/j.1479-8425.2006.00193.x
– volume: 59
  start-page: 230
  year: 2006
  ident: B70
  article-title: D-alanine added to antipsychotics for the treatment of schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2005.06.032
– volume: 309
  start-page: R561
  year: 2015
  ident: B121
  article-title: N-methyl-d-aspartate receptor coagonist D-serine suppresses intake of high-preference food
  publication-title: Am J Physiol Regul Integr Comp Physiol.
  doi: 10.1152/ajpregu.00083.2015
– volume: 8
  start-page: 191
  year: 2021
  ident: B5
  article-title: Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(20)30513-7
– volume: 159
  start-page: 226
  year: 2014
  ident: B153
  article-title: Basic visual dysfunction allows classification of patients with schizophrenia with exceptional accuracy
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2014.07.052
– volume: 9
  start-page: 14
  year: 2018
  ident: B39
  article-title: Potential and challenges for the clinical use of D-Serine as a cognitive enhancer
  publication-title: Front Psychiatry.
  doi: 10.3389/fpsyt.2018.00014
– volume: 757
  start-page: 119
  year: 2001
  ident: B23
  article-title: Determination of free D-aspartic acid, D-serine and D-alanine in the brain of mutant mice lacking D-amino acid oxidase activity
  publication-title: J Chromatogr B Biomed Sci Appl.
  doi: 10.1016/S0378-4347(01)00131-1
– volume: 21
  start-page: 803
  year: 1946
  ident: B84
  article-title: The influence of age and species on the nephrotoxic action of DL-serine
  publication-title: Am J Pathology.
– volume-title: The Scale for the Assessment of Negative Symptoms (SANS)
  year: 1984
  ident: B68
– volume: 5
  start-page: e200018
  year: 2020
  ident: B10
  article-title: Grant report on D-serine augmentation of neuroplasticity-based auditory learning in schizophrenia (dagger)
  publication-title: J Psychiatr Brain Sci
  doi: 10.20900/jpbs.20200018
– volume: 65
  start-page: 454
  year: 1995
  ident: B34
  article-title: Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration
  publication-title: J Neurochem.
  doi: 10.1046/j.1471-4159.1995.65010454.x
– volume: 243
  start-page: 177
  year: 2008
  ident: B93
  article-title: D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response
  publication-title: Toxicology.
  doi: 10.1016/j.tox.2007.10.009
– volume: 5
  start-page: e561
  year: 2015
  ident: B65
  article-title: D-serine levels in Alzheimer's disease: implications for novel biomarker development
  publication-title: Transl Psychiatry.
  doi: 10.1038/tp.2015.52
– volume: 78
  start-page: 163
  year: 1993
  ident: B148
  article-title: Effects of ketamine on cardiovascular responses mediated by N-methyl-D-aspartate receptor in the rat nucleus tractus solitarius
  publication-title: Anesthesiology.
  doi: 10.1097/00000542-199301000-00022
– volume: 97
  start-page: 4926
  year: 2000
  ident: B37
  article-title: D-serine is an endogenous ligand for the glycine site of the N-methyl-D- aspartate receptor
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.97.9.4926
– volume: 164
  start-page: 421
  year: 2019
  ident: B151
  article-title: Altered profiles and metabolism of l- and d-amino acids in cultured human breast cancer cells vs. non-tumorigenic human breast epithelial cells
  publication-title: J Pharm Biomed Anal.
  doi: 10.1016/j.jpba.2018.10.047
– volume: 300
  start-page: C22
  year: 2011
  ident: B80
  article-title: Functional NMDA receptors with atypical properties are expressed in podocytes
  publication-title: Am J Physiol Cell Physiol.
  doi: 10.1152/ajpcell.00268.2010
– volume: 470
  start-page: 395
  year: 2018
  ident: B144
  article-title: Glutamatergic, GABAergic, and endocannabinoid neurotransmissions within the dorsal hippocampus modulate the cardiac baroreflex function in rats
  publication-title: Pflugers Arch.
  doi: 10.1007/s00424-017-2083-y
– volume: 157
  start-page: 107681
  year: 2019
  ident: B64
  article-title: A novel NMDA receptor-based intervention to suppress compulsion-like alcohol drinking
  publication-title: Neuropharmacology.
  doi: 10.1016/j.neuropharm.2019.107681
– volume: 19
  start-page: 157
  year: 1987
  ident: B95
  article-title: Immunoelectron microscopic localization of D-amino acid oxidase in rat kidney and liver
  publication-title: Histochem J.
  doi: 10.1007/BF01695140
– volume: 83
  start-page: 108
  year: 2010
  ident: B12
  article-title: N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
  publication-title: Brain Res Bull.
  doi: 10.1016/j.brainresbull.2010.04.006
– volume: 9
  start-page: 5104
  year: 2019
  ident: B106
  article-title: D-Serine reflects kidney function and diseases
  publication-title: Sci Rep.
  doi: 10.1038/s41598-019-41608-0
– volume: 65
  start-page: 1103
  year: 2009
  ident: B163
  article-title: Co-Administration of a d-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2009.01.002
– volume: 35
  start-page: 236
  year: 2021
  ident: B3
  article-title: Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials
  publication-title: J Psychopharmacol.
  doi: 10.1177/0269881120965937
– volume: 207
  start-page: 63
  year: 2019
  ident: B74
  article-title: Association between increased serum D-serine and cognitive gains induced by intensive cognitive training in schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2018.04.011
– volume: 21
  start-page: 156
  year: 1998
  ident: B90
  article-title: Urinary excretion of D-serine in human: comparison of different ages and species
  publication-title: Biol Pharm Bull.
  doi: 10.1248/bpb.21.156
– volume: 40
  start-page: 1405
  year: 2015
  ident: B126
  article-title: The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2014.326
– volume: 77
  start-page: e27
  year: 2015
  ident: B51
  article-title: Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2014.08.023
– volume: 713
  start-page: 16
  year: 2013
  ident: B143
  article-title: Involvement of N-methyl-D-aspartate glutamate receptor and nitric oxide in cardiovascular responses to dynamic exercise in rats
  publication-title: Eur J Pharmacol.
  doi: 10.1016/j.ejphar.2013.04.046
– volume: 7
  start-page: 11881
  year: 2016
  ident: B63
  article-title: The effect of D-serine administration on cognition and mood in older adults
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.7691
– volume: 16
  start-page: 191
  year: 2018
  ident: B119
  article-title: Chronic D-serine supplementation impairs insulin secretion
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2018.07.002
– volume: 30
  start-page: 209
  year: 1979
  ident: B89
  article-title: Renal tubular necrosis induced by compounds structurally related to D-serine
  publication-title: Exp Mol Pathol.
  doi: 10.1016/0014-4800(79)90054-6
– volume: 634
  start-page: 42
  year: 2016
  ident: B46
  article-title: Low D-serine levels in schizophrenia: a systematic review and meta-analysis
  publication-title: Neurosci Lett.
  doi: 10.1016/j.neulet.2016.10.006
– volume: 2
  start-page: 403
  year: 2015
  ident: B47
  article-title: D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(15)00098-X
– volume: 12
  start-page: 514579
  year: 2021
  ident: B75
  article-title: Impairment of executive functions associated with lower D-serine serum levels in patients with schizophrenia
  publication-title: Front Psychiatry.
  doi: 10.3389/fpsyt.2021.514579
– volume: 77
  start-page: 269
  year: 1974
  ident: B85
  article-title: The nature of D-serine–induced nephrotoxicity
  publication-title: Am J Pathol.
– volume: 280
  start-page: 1754
  year: 2005
  ident: B20
  article-title: Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M405726200
– volume: 182
  start-page: 90
  year: 2017
  ident: B7
  article-title: Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2016.10.027
– volume: 21
  start-page: 803
  year: 1945
  ident: B83
  article-title: Renal injury in the rat following the administration of serine by stomach tube
  publication-title: Am J Pathology.
– volume: 53
  start-page: 704
  year: 1974
  ident: B146
  article-title: The role of baroreceptors in the cardiovascular response to ketamine
  publication-title: Anesth Analg.
  doi: 10.1213/00000539-197409000-00015
– volume: 30
  start-page: 201
  year: 2015
  ident: B113
  article-title: Insulin treatment prevents the increase in D-serine in hippocampal CA1 area of diabetic rats
  publication-title: Am J Alzheimers Dis Other Demen.
  doi: 10.1177/1533317514545379
– volume: 59
  start-page: 853
  year: 2011
  ident: B28
  article-title: Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice
  publication-title: Neurochem Int.
  doi: 10.1016/j.neuint.2011.08.017
– volume: 18
  start-page: 1678
  year: 2005
  ident: B29
  article-title: D-amino-acid oxidase is involved in D-serine-induced nephrotoxicity
  publication-title: Chem Res Toxicol.
  doi: 10.1021/tx0500326
– year: 2021
  ident: B138
  article-title: Oral administration of D-serine prevents the onset and progression of colitis in mice
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-021-01792-1.
– volume: 70
  start-page: 1267
  year: 2013
  ident: B155
  article-title: Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor
  publication-title: JAMA Psychiatry.
  doi: 10.1001/jamapsychiatry.2013.2159
– volume: 689
  start-page: 21
  year: 2019
  ident: B44
  article-title: The plastic D-serine signaling pathway: sliding from neurons to glia and vice-versa
  publication-title: Neurosci Lett.
  doi: 10.1016/j.neulet.2018.05.039
– volume: 34
  start-page: 1709
  year: 1986
  ident: B94
  article-title: Immunocytochemical localization of D-amino acid oxidase in the central clear matrix of rat kidney peroxisomes
  publication-title: J Histochem Cytochem.
  doi: 10.1177/34.12.2878022
SSID ssj0000399365
Score 2.3882768
SecondaryResourceType review_article
Snippet Background: D- Serine, a direct, full agonist at the D- serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been...
Background:D-Serine, a direct, full agonist at the D-serine/glycine modulatory site of the N-methyl-D-aspartate-type glutamate receptors (NMDAR), has been...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 726365
SubjectTerms D-serine
kidney
NMDA–N-methyl-D-aspartate
Psychiatry
safety
schizophrenia
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS8MwFA7iyYsoKs5fVPA0iGubNkm9zekYgl7mYLeQnyhIN1x32H_vS9qN9qIXr23aJt8L-d7rS76H0B1hhUl1pjCQgcNZnhqsKDFYcwjjnIu5df6g8Osbncyyl3k-b5X68nvCanngGriBMYwQV-SpVVkmIWAzGZe-XHyqEtoogQLntYKpsAZ73qV5ncaEKKwYuOVq4_dOpsk9SynxZNIioqDX33Eyu1skW5wzPkKHjbMYDetOHqM9W56g_hOehjN7D9EwGvl3R6GIvF1F9Y_-aOGiqXS22pyi2fj5fTTBTcUDrMFRqrDRLncMnKZYMliFdKxTRbWTjOiUWMUMBxwcp9zkgIMk3Pg8SuEMjzXnOiZnaL9clPYcRYSaBNhHAyNLH8RIyTOVF0oljBRUkR6Kt8MXupED91UpvgSEBR4xERATHjFRI9ZD_d0jy1oL47fGjx7TXUMvYx0ugHFFY1zxl3F76HZrEQHT3ucyZGkX65UAT40C-RYEBsI6pup8sXun_PwIAtqccOBudvEfXbxEB37UOKjkXqH96nttr8FPqdRNmJI_NCnkWQ
  priority: 102
  providerName: Directory of Open Access Journals
Title D-Serine: A Cross Species Review of Safety
URI https://www.proquest.com/docview/2566036933
https://pubmed.ncbi.nlm.nih.gov/PMC8384137
https://doaj.org/article/dd733f952eb44a788d48a10562b16004
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fSxwxEA5X--JLUdri1Sor9EmI3d1kk6wg4o-KFM4XPbi3kJ9akD17d4L33zuT3TtckNLX3STLTDb5vo9JZgj5wWTtS8ctBTCIlFelp1YwT50CGRdjrkLEi8KjG3E95r8n1WRAVuWtOgfO35V2WE9qPHs8evm7PIUFf4KKE_D2Z3yaL_FYZFkcyVIwUX0gHwGYJBY0GHVsP23MCMapuGQhBKcYw2rjnO-P0kOqlNC_x0L7ZyjfgNLVFvnUscnsrJ3-bTIIzWdyeElv06W-4-wsu8Cxs1RlPsyzNhKQTWN2a2JYLL-Q8dWvu4tr2pVEoA6Y1IJ6F6sogVXlRsI25XJXWuGikcyVLFjpVVWGqITylfLcMOUx0FJHr3KnlMvZV7LRTJuwQzImfAHw5ACyDaocYxS3VW1tIVktLBuSfGW-dl2-cCxb8ahBN6DHdPKYRo_p1mNDcrju8tQmy_hX43P06boh5rlOD6aze90tG-29ZCzWYJTl3IBc91yZAkmbLYCq8SE5WM2IhnWBwQ7ThOnzXAOVE4DONQNDZG-qel_sv2n-PKQM24opAHf57T9G3yWbaBRNWXK_k43F7DnsAU9Z2P2k7_fTP_gK3mflvw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=D-Serine%3A+A+Cross+Species+Review+of+Safety&rft.jtitle=Frontiers+in+psychiatry&rft.au=Meftah%2C+Amir&rft.au=Hasegawa%2C+Hiroshi&rft.au=Kantrowitz%2C+Joshua+T&rft.date=2021-08-10&rft.issn=1664-0640&rft.eissn=1664-0640&rft.volume=12&rft.spage=726365&rft_id=info:doi/10.3389%2Ffpsyt.2021.726365&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-0640&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-0640&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-0640&client=summon